BriaCell Therapeutics Corp.
BCTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. The $29.9M market capitalization puts BCTX squarely in micro-cap range for its industry. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Market Cap
$29.9M
Beta
1.51
P/E (TTM)
—
P/E (Fwd)
-8.81
EPS (TTM)
$-0.87
EPS (Fwd)
$-0.39
ROE
-175.3%
ROA
-90.8%
Cash
$22.8M
Total Debt
$0
Free CF
-$20.0M
52W Change
-74.4%
Annual Financials
Cash vs Debt
Where BCTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BCTX finished 9.63% below its 150-day moving average ($3.74) and 15.50% below its 200-day moving average ($4.00). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BCTX overbought or oversold?
At the October 20, 2026 close, BCTX's RSI(14) was 27.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BriaCell Therapeutics Corp. reports $22.8M in cash and $0 in total debt. Free cash flow is running at -$20.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -175.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.51 means BCTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing BCTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.